Society of Gynecologic Oncology Recommendations for the Prevention of Ovarian Cancer

2015 ◽  
Vol 70 (7) ◽  
pp. 448-449
Author(s):  
Joan L. Walker ◽  
C. Bethan Powell ◽  
Lee-May Chen ◽  
Jeanne Carter ◽  
Victoria L. Bae Jump ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology

scholarly journals Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper

2014 ◽  
Vol 132 (1) ◽  
pp. 8-17 ◽  
Author(s):  
Thomas J. Herzog ◽  
Deborah K. Armstrong ◽  
Mark F. Brady ◽  
Robert L. Coleman ◽  
Mark H. Einstein ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trial ◽  
Gynecologic Oncology ◽  
White Paper ◽  
Cancer Clinical Trial ◽  
Clinical Trial Endpoints ◽  
Trial Endpoints

scholarly journals FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper

2017 ◽  
Vol 147 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Thomas J. Herzog ◽  
Gwynn Ison ◽  
Ronald D. Alvarez ◽  
Sanjeeve Balasubramaniam ◽  
Deborah K. Armstrong ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trial ◽  
Gynecologic Oncology ◽  
White Paper ◽  
Cancer Clinical Trial ◽  
Clinical Trial Endpoints ◽  
Trial Endpoints

scholarly journals Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer

2020 ◽  
Vol 16 (7) ◽  
pp. 225-246 ◽  
Author(s):  
Carolyn E Haunschild ◽  
Krishnansu S Tewari
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Double Blind ◽  
Free Survival ◽  
Platinum Sensitive ◽  
The Us ◽  
Us Fda

On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National Cancer Institute-sponsored Gynecologic Oncology Group (GOG) protocol 0218, the Phase III, randomized, placebo-controlled, double-blind, multi-center and multi-national clinical trial that met its primary end point, progression-free survival. Bevacizumab is now approved in the frontline, platinum-sensitive recurrent and platinum-resistant recurrent settings for epithelial ovarian cancer. This review will address the broad range of clinical trials addressing the efficacy of bevacizumab use in ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document